The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer

Abramson Cancer Center at Penn Medicine1 site in 1 country100 target enrollmentMarch 2015

ConditionsNon-small Cell Lung Cancer (NSCLC)

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Non-small Cell Lung Cancer (NSCLC)
Sponsor: Abramson Cancer Center at Penn Medicine
Enrollment: 100
Locations: 1
Primary Endpoint: Number of adverse events
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The primary objective of this study is to determine whether circulating tumor cells (CTCs) can be used as a non-invasive means of confirming pathologic diagnosis in early-stage (Stage I) non-small cell lung cancer (NSCLC). Patients scheduled to undergo surgical intervention will have blood samples obtained to test for CTCs. Presence of CTCs will be compared to final pathologic diagnosis based on surgical specimens to assess the sensitivity of using CTCs alone to make a definitive diagnosis.

Registry

clinicaltrials.gov

Start Date

March 2015

End Date

December 31, 2019

Last Updated

6 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Abramson Cancer Center at Penn Medicine

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Clinical diagnosis of stage I NSCLC a. Only patients with a pathologically confirmed NSCLC will be retained for data analysis b. Should pathologic diagnosis reveal a more advanced stage, these subjects will remain in the study
•18 years of age
•Ability to read and sign informed consent
•Both men and women and members of all races and ethnic groups are eligible for this trial.